In case you missed it: March 22 to March 26

This week's top articles included:

Nextstellis combined oral contraceptive and endocrine markers

Limited changes occur in endocrine markers with the combined oral contraceptive Nextstellis (Mayne Pharma), according to a prospective study presented at the virtual annual meeting of the International Society for the Study of Women's Sexual Health (ISSWSH) in March.

Hominis surgical robot receives De Novo marketing authorization

The privately held medical device firm Memic Innovative Surgery Ltd. announced in early March that the Food and Drug Administration (FDA) has granted De Novo marketing authorization for its Hominis, a robot-assisted surgical platform for use in single site, natural orifice laparoscopic-assisted transvaginal benign gynecologic procedures, including benign hysterectomy.

Time Sensitive: Sign up soon to participate in Expert Panel

Panel will be focused on early detection, screening, and treatment of ovarian cancer.